Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company

Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company

CNBC Halftime Report

Eli Casdin & Keith Meister of CM Life Sciences, and Sema4 CEO, Eric Schadt, talked to CNBC about how their plans to go public will help them deliver on transforming clinical & life sciences through better leveraging of data.

CM Life Sciences Merger Announcement

CM Life Sciences announces combination with Sema4, a Disruptive AI-driven Genomic & Clinical Data Platform Company, to Accelerate Growth

Final Prospectus

As filed with the Securities and Exchange Commission

CM Life Sciences IPO Pricing Announcement

CM Life Sciences, Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $385 Million Initial Public Offering

SEC Filing

Link to all items filed with the Securities and Exchange Commission